Donepezil is a cholinesterase inhibitor approved for the symptomatic treatment of AD that was reported to reduce Aβ levels in vitro, in the brain of a transgenic model of AD and in the serum of AD patients [43–46], and to increase the levels of tau protein in SH-SY5Y cells [47]. The gene discussed is MAPT; the disease is Alzheimer disease.